Stay updated on Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedA new Locations section is added showing the Chicago, Illinois site; the standalone Illinois Locations entry was removed, and the revision updated to v3.3.3.SummaryDifference0.2%

- Check19 days agoChange DetectedTwo timestamp labels in the Study Record Dates area were updated to include (Estimated), changing Results First Posted (Estimated) and Last Update Posted (Estimated). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check26 days agoChange DetectedStudy status updated to Terminated due to drug supply no longer available. Results for primary and secondary outcomes have been posted.SummaryDifference2%

- Check40 days agoChange DetectedThe page revision history has been updated: Revision: v3.3.2 was added and Revision: v3.2.0 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page now displays a 'Results Submitted' indicator, and the 'No Results Posted' and the government funding status notices were removed.SummaryDifference0.5%

- Check62 days agoChange DetectedNo additions or deletions were detected on the page; the study details and layout appear the same as before.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page.